Literature DB >> 15788640

Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.

J A Vendrell1, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, P A Cohen.   

Abstract

The aim of this study was to explore the pharmacological response to 4-hydroxy-tamoxifen (OH-Tam) and to estradiol (E2) in three cell lines: MVLN, a human breast carcinoma cell line derived from MCF-7, and two MVLN-derived OH-Tam-resistant (OTR) cell lines, called CL6.8 and CL6.32. The OH-Tam response in the OTR cells was associated with the development of both an agonist activity of the drug on cell proliferation and the resistance of the cells to OH-Tam-induced apoptosis. The OTR cells also developed an increased sensitivity to the E2 growth-stimulating activity. To delineate the genes that determine such responses, we combined a mini-array-based gene-selection approach and an extensive real-time quantitative PCR exploration in the MVLN and OTR cell lines exposed to three pharmacological conditions: a 4-day treatment with E2, OH-Tam or both E2 and OH-Tam. Compiled data revealed a hyper-response to E2 and a modification of the OH-Tam pharmacological response (loss of antagonist action and agonist activity) at the gene-expression level. The proteins encoded by the genes selected in this study have been reported to be involved in the regulation of cell proliferation, cell transformation, DNA repair and apoptosis, or belong to the ErbB/epidermal growth factor receptor-driven pathway. Our data also provide evidence of changes in transcriptional co-regulator expression, elevated mitogen-activated protein kinase activity and increase in the phosphorylation status of estrogen receptor alpha on serine residue 118 in the OTR cell lines, suggesting the possible involvement of such mechanisms in the agonist activity of OH-Tam and/or the hyper-response of cells to E2. Taken together, our study should enhance our knowledge of the multifactorial events associated with the development of Tam resistance in two independent cell lines issued from the same selection process and should help in the identification of potential molecular targets for diagnosis or therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788640     DOI: 10.1677/erc.1.00899

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  17 in total

1.  Headway in resistance to endocrine therapy in breast cancer.

Authors:  Yali Xu; Qiang Sun
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

Review 2.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

Review 3.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

4.  MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.

Authors:  J Cui; Y Yang; H Li; Y Leng; K Qian; Q Huang; C Zhang; Z Lu; J Chen; T Sun; R Wu; Y Sun; H Song; X Wei; P Jing; X Yang; C Zhang
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

5.  Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.

Authors:  C Elizabeth Caldon; Elizabeth A Musgrove
Journal:  Cell Div       Date:  2010-01-17       Impact factor: 5.130

6.  ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.

Authors:  Aurélie Thollet; Julie A Vendrell; Léa Payen; Sandra E Ghayad; Sabrina Ben Larbi; Evelyne Grisard; Colin Collins; Marie Villedieu; Pascale A Cohen
Journal:  Mol Cancer       Date:  2010-11-08       Impact factor: 27.401

7.  Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

Authors:  Francesca De Amicis; Janagi Thirugnansampanthan; Yukun Cui; Jennifer Selever; Amanda Beyer; Irma Parra; Nancy L Weigel; Matthew H Herynk; Anna Tsimelzon; Michael T Lewis; Gary C Chamness; Susan G Hilsenbeck; Sebastiano Andò; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-06-17       Impact factor: 4.872

Review 8.  Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Authors:  Eric Badia; Joan Oliva; Patrick Balaguer; Vincent Cavaillès
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Authors:  Nhan T Nguyen; Julie A Vendrell; Coralie Poulard; Balázs Győrffy; Sophie Goddard-Léon; Ivan Bièche; Laura Corbo; Muriel Le Romancer; Thomas Bachelot; Isabelle Treilleux; Pascale A Cohen
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

10.  A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Authors:  Julie A Vendrell; Katherine E Robertson; Patrice Ravel; Susan E Bray; Agathe Bajard; Colin A Purdie; Catherine Nguyen; Sirwan M Hadad; Ivan Bieche; Sylvie Chabaud; Thomas Bachelot; Alastair M Thompson; Pascale A Cohen
Journal:  Breast Cancer Res       Date:  2008-10-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.